Dick Tracy has nothing on the wearable gadgets under development to help people better police their diabetes. Wearable technologies in its totality — which include Google Glass and the Apple Watch — are part of a booming market that’s expected to swell to $20 billion by 2015 and is further expected to grow at a compound annual growth rate of nearly 40% over the next six years.
Close to half (40%) of the U.S. adult population — roughly 126 million — is expected to develop Type 2 diabetes at some point during their lifetime, according to a study published in The Lancet Diabetes and Endocrinology in August.
Mylan announced that its subsidiary, Mylan Labs Limited, has signed an agreement with Gilead Science under which Mylan has been licensed the non-exclusive rights to manufacture and distribute sofosbuvir and the investigational single tablet regimen of ledipasvir/sofosbuvir in 91 developing countries.
Lupin Limited and Salix Pharmaceuticals on Friday announced that they have entered into a definitive distribution agreement under which Salix has granted Lupin the exclusive right to market, distribute and sell certain Salix products in Canada.
Close to 100 million wearable, remote patient-monitoring devices will ship over the next five years, according to ABI Research, boosted by growing interest and awareness about the benefits of supporting healthcare away from the hospital and into patients’ homes.